Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q3SYG4 (
C18
)
23,707
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aromatase, a cytochrome P-450, catalyzes the formation of aromatic
C18
estrogenic steroids from C19 androgens. DNA sequence analysis of the human
aromatase
gene has revealed that a putative promoter sequence exists immediately up-stream of the second exon. Chloramphenicol acetyltransferase functional analyses of cells transfected with chloramphenicol acetyltransferase expression plasmids containing various DNA fragments derived from the 3'-end of the first intron of the
aromatase
gene were performed to show that a promoter indeed exists in this region. However, in all of the cell lines used in this study, MCF-7, JAR, OVCAR-3, and skin fibroblast, the function of this promoter was inhibited by a negative regulatory element situated up-stream from the promoter. The results further suggest that this inhibitory element behaves as a silencer element, in that it could inhibit a simian virus-40 promoter from a distance of several kilobases. This negative element worked in both orientations and inhibited the functions of several promoters, including the newly identified promoter situated in the 3'-end of the first intron of the human
aromatase
gene. Primer extension analysis has been performed to determine the potential transcription start site. The mechanism of the regulation of
aromatase
expression is known to be very complex. The presence of a promoter and a silencer at the 3'-end of the first intron may represent one additional way that
aromatase
expression is controlled in estrogen-producing cells.
...
PMID:Identification of a promoter and a silencer at the 3'-end of the first intron of the human aromatase gene. 133 79
Aromatase, a cytochrome P-450, catalyzes the formation of aromatic
C18
estrogenic steroids from C19 androgens. Using the x-ray structure of cytochrome P-450cam as the model, seven mutants of human
aromatase
were designed and expressed in Chinese hamster ovary cells by a stable expression method. They are His-128----Gln, His-128----Ala, Cys-299----Ala, Glu-302----Leu, Asp-309----Asn, Asp-309----Ala, and Ser-312----Cys. The presence of the
aromatase
mutants in the transfected Chinese hamster ovary cells were confirmed by immunoprecipitation analysis. The kinetic parameters of these mutants using [1 beta,2 beta-3H] androstenedione (or [1 beta-3H]androstenedione), and [1 beta,2 beta-3H]testosterone as substrates were determined. In addition, inhibition profiles for these mutants with two
aromatase
inhibitors, 4-hydroxyandrostenedione and aminoglutethimide were obtained. Furthermore, the reactions catalyzed by these mutants were examined by evaluating the levels of the product estrone, and two intermediates, 19-hydroxyandrostenedione and 19-oxoandrostenedione by reverse phase high performance liquid chromatography using [7-3H]androstenedione as the substrate. Our results indicate that among the positions we modified, Asp-309 appears to be very important for the enzyme catalysis.
...
PMID:A site-directed mutagenesis study of human placental aromatase. 173 Jun 67
Aromatase cytochrome P-450 (cytochrome P-450AROM) catalyzes the formation of aromatic
C18
estrogenic steroids from C19 androgens. Several studies indicate that cytochrome P-450AROM activity is induced by glucocorticoids such as dexamethasone (DEX) and superinduced by DEX plus cycloheximide (CHX). We have used cultured human skin fibroblasts as a model system to investigate the regulation of
aromatase
gene expression. Whereas Northern blot analysis of total cellular RNA or poly (A)+ RNA from untreated strains of normal human skin fibroblasts failed to demonstrate any hybridization with a specific human placental cytochrome P-450AROM complementary DNA, analysis of RNA from cells treated with DEX demonstrated hybridization of the cytochrome P-450AROM complementary DNA to two transcripts of about 2.5 and 3.0 kilobases. Incubation of cells with DEX plus CHX resulted in a further increase in levels of cytochrome P-450AROM messenger RNA (mRNA) when compared to cells treated with DEX alone, suggesting that inhibition of protein synthesis superinduces transcription of the cytochrome P-450AROM gene. By contrast, levels of beta-actin mRNA were not affected by treatment with DEX and CHX. Treatment of cells with CHX alone did not produce a change in either
aromatase
activity or levels of cytochrome P-450AROM mRNA transcripts. These results indicate that
aromatase
activity is regulated by changes in the concentration of cytochrome P-450AROM mRNA, and imply that control of cytochrome P-450AROM gene expression is at the level of gene transcription. We conclude that the cytochrome P-450AROM gene is regulated by a complex mechanism that includes both positive and negative transcription factors.
...
PMID:Induction and superinduction of messenger ribonucleic acid specific for aromatase cytochrome P-450 in cultured human skin fibroblasts. 174 Apr 98
The present studies were conducted to define the pathway(s) by which androstenedione is metabolized in porcine granulosa cells (pGC) and determine whether metabolism of this steroid is affected by in vitro luteinization. pGC isolated from large preovulatory follicles were cultured for up to 2 days in the presence of 5 microM unlabeled or [4-14C]-labeled androstenedione. Metabolism of androstenedione was assessed by HPLC, using in-line liquid scintillation detection. Metabolite identification was confirmed by gas chromatography-mass spectrometry of HPLC fractions isolated from medium conditioned by granulosa cells (pGCCM) cultured for 48 h in the presence of unlabeled androstenedione. The metabolites identified were 19-oic-androstenedione (3,17-dioxo-4-androsten-19-oic acid), 19-hydroxytestosterone, 19-hydroxyandrostenedione, 19-nor-testosterone, an estrenolone of as yet unproven stereoisomerism, 5(10)-estrene-3 beta, 17 beta-diol, 17 beta-estradiol, testosterone, and 19-nor-androstenedione. Results indicate that 19-nor-androstenedione is artifactually derived from 19-oic-androstenedione as a result of degradation in storage and during isolation. After metabolite identification, studies of the time course of androstenedione metabolism by pGC during in vitro luteinization were conducted. 17 beta-Estradiol and 19-oic-androstenedione were the predominant metabolites, and accumulation of these steroids was virtually identical. Production of these metabolites was maximal during the first 12 h of culture. The accumulation of 5(10)-estrene-3 beta,17 beta-diol and 19-nor-testosterone was maximal at 48 h of culture, with 5(10)-estrene-3 beta,17 beta-diol consistently accumulating in greater concentrations than 19-nor-testosterone. Aromatase activity of pGC was negligible from 36-48 h of culture, as demonstrated by minimal accumulation of 17 beta-estradiol during this period of culture. The accumulation of 19-oic-androstenedione, 5(10)-estrene-3 beta,17 beta-diol, and 19-nor-testosterone was also negligible during this latter time period, suggesting that their formation is associated with
aromatase
. From these results, pGC from preovulatory follicles undergoing luteinization in vitro lose the ability to convert androstenedione to estrogens. The formation of 19-oic-androstenedione, shown here for the first time, parallels the formation of 17 beta-estradiol, and this acidic steroid is proposed to be a product of
aromatase
. As reported in previous studies, pGC do produce
C18
neutral steroids from exogenous androstenedione. The production of these steroids requires an active
aromatase
to produce their immediate precursor, which is here hypothesized to be 19-oic-androstenedione. However, their maximal production does not commence until
aromatase
activity has declined, and it is hypothesized that their production depends on modifications in steroid metabolism associated with luteinization.
...
PMID:Androgen metabolism by porcine granulosa cells during the process of luteinization in vitro: identification of 19-oic-androstenedione as a major metabolite and possible precursor for the formation of C18 neutral steroids. 195 79
Estrogen formation from androst-4-ene-3,17-dione and its kinetics were studied using microsomes from rat hypothalamus. [4-14C] androst-4-ene-3,17-dione and a homogenate of rat hypothalamus were incubated in the presence of NADPH at 37 degrees C for 3 hrs. The estrogen fraction was extracted from the incubation mixture with ethyl acetate, purified by column chromatography on Sephadex LH-20 and Bond Elut
C18
, and separated into estrone and estradiol fractions by HPLC. In analysis of the trimethylsilyl (TMS) derivatives of each fraction by gas chromatography-mass spectrometry (GC-MS), the molecular ion peak of the estrone fraction appeared at m/z 344, within 2 amu of that for the TMS derivative of natural estrone. The retention time of the estrone fraction derivative was 11.6 min, the same as that of natural estrone. 14C-estrone was thus concluded to be biosynthesized from [4-14C]-androst-4-ene-3,17-dione in rat hypothalamus. The kinetics of the
aromatase
of rat hypothalamic tissue was studied by measuring 3H2O released from [1 beta-3H]-androst-4-ene-3,17-dione and estrone as the estrogen product by measured gas chromatography selected ion monitoring (GC-SIM). High correlation was found between 3H2O release and estrone measured by GC-SIM (r = 0.97). Aromatase activity was linear with respect to incubation time and quantity of tissue. Km and Vmax were 30.3 nM and 7.98 fmol estrogen/h/mg of wet tissue, respectively. 4-hydroxyandrostenedione (4-OH-A) suppressed the activity of
aromatase
in both rat hypothalamic and human placental tissue in a concentration-dependent manner. Polyclonal IgG to human placental
aromatase
also suppressed
aromatase
activity of human placental tissue, but only slightly suppressed that of rat hypothalamus. The molecular structure of
aromatase
in rat hypothalamus was thus concluded to differ from that in human placenta.
...
PMID:[Estrogen formation in the central nervous system and characteristics of aromatase of rat hypothalamus]. 204 Mar 68
The origin and biosynthesis of 4-oestrene-3,17-dione (19-norandrostenedione), a major steroid in porcine ovarian follicular fluid, was investigated by culturing granulosa cells from 4-6 mm follicles of prepubertal gilts with radiolabelled androstenedione and 19-hydroxyandrostenedione. Steroid metabolites were purified by solvent extraction and lipophilic column chromatography, and analysed by
C18
reverse-phase high-performance liquid chromatography. 19-Hydroxyandrostenedione, 19-norandrostenedione and oestradiol-17 beta were obtained as major metabolites from androstenedione, while 19-norandrostenedione and oestradiol-17 beta were the major products from 19-hydroxyandrostenedione. Serum alone or serum plus FSH significantly enhanced formation of 19-norandrostenedione and oestradiol-17 beta from each substrate, compared with controls. Micromolar concentrations (1 mumol/l) of 4-hydroxyandrostenedione, an
aromatase
inhibitor, significantly reduced formation of 19-norandrostenedione and oestradiol-17 beta by granulosa cells cultured with serum and FSH. Formation of 19-norandrostenedione and oestradiol-17 beta from androstenedione and 19-hydroxyandrostenedione was also significantly inhibited by aminoglutethimide phosphate, a cytochrome P-450 inhibitor known to block the conversion of androstenedione to oestrogens. Ketoconazole, an inhibitor of the cytochrome P-450 dependent 17,20-lysase, blocked formation of 19-norandrostenedione and oestradiol-17 beta only at millimolar concentrations. These results suggest that 19-norsteroid and oestrogen formation from C19 aromatizable androgens may share a common or overlapping pathway, and imply that 19-norsteroid and oestrogen synthesis is mediated by cytochrome P-450 dependent enzymes.
...
PMID:Formation of 4-oestrene-3,17-dione (19-norandrostenedione) by porcine granulosa cells in vitro is inhibited by the aromatase inhibitor 4-hydroxyandrostenedione and the cytochrome P-450 inhibitors aminoglutethimide phosphate and ketoconazole. 292 99
A thermostable peptide, inducing sperm release in Rana esculenta L. and having immunological properties which resemble those of the gonadotropins but nonidentical with any one of the gonadotropins or their subunits, has been prepared from pars distalis of bovine anterior pituitaries by means of acetic acid extraction, heating, ethanol precipitation, and reverse-phase high-performance liquid chromatography (HPLC). During the purification, the biological activity was regularly followed by means of the potency of collected fractions to induce sperm release in frogs. Using HPLC (5 micron
C18
silica), the activity was eluted with 38% of acetonitrile:water:trifluoroacetic acid (80:19.5:0.5) and 62% of 0.5% trifluoroacetic acid, pH 3.3. The active principle was also found to bind to a rat ovarian follitropin (FSH) receptor. In contrast, bovine FSH and LH treated identically to the peptide lost all such affinity, indicating that the peptide is not created from either of these during the purification procedure. Further, the peptide was, like FSH, also shown to stimulate
aromatase
activity in intact Sertoli cells from immature male rats in vitro.
...
PMID:A gonadotropin-like thermostable peptide, prepared from bovine anterior pituitary, inducing spermiation in the frog Rana esculenta (L.) and binding to a rat ovarian FSH receptor. 300 Aug 63
19-Oxoandrostenedione, the product of 19-hydroxyandrostenedione by the 19-oxidase activity of the purified P-450(11)beta system of adrenal cortex mitochondria, was further oxidized and demethylated at the 10-position to give the
C18
-steroids, estrone (
aromatase
reaction) and 19-norandrostenedione (nonaromatizing 10-demethylase or C10-19 lyase reaction). These reactions, together with the initial hydroxylation of androstenedione at C19, form a sequence of P-450(11)beta-catalyzed C19-steroid 19-monooxygenase reactions. P-450(11)beta is thus similar to placental endoplasmic P-450AROM in some of its substrate specificity, but the two forms of P-450 appear to be different in both physiology and properties.
...
PMID:Aromatase and nonaromatizing 10-demethylase activity of adrenal cortex mitochondrial P-450(11)beta. 326 34
The biosynthesis of non-aromatic 19-norsteroids has been studied using primary cultures of porcine granulosa cells. Formation of 5(10)-estrene-3 beta,17 beta-diol, a novel 19-norsteroid, from androstenedione and 19-hydroxyandrostenedione by porcine granulosa cells is reported for the first time. The structure was deduced from (i) comparison of its elution times on
C18
reverse phase HPLC with authentic 5(10)-estrene-3 beta,17 beta-diol (ii) identification with 5(10)-estrene-3 beta,17 beta-diol-diacetate after acetylation (iii) oxidation/acid catalysed isomerization to 19-norandrostenedione. Serum or serum plus FSH significantly stimulated (seven fold increase) formation of 5(10)-estrene-3 beta,17 beta-diol from androstenedione and 19-hydroxyandrostenedione. Formation of 5(10)-estrene-3 beta,17 beta-diol from both substrates was significantly (p less than 0.01) reduced by the
aromatase
inhibitors 4-hydroxyandrostenedione (15 microM) and aminoglutethimide phosphate (10(-4)M). These results suggest that 5(10)-estrene-3 beta,17 beta-diol (and 19-norandrostenedione) may be formed by enzymes similar to the
aromatase
complex required for estradiol-17 beta biosynthesis. 5(10)-Estrene-3 beta,17 beta-diol is converted by granulosa cells to four metabolites. 19-Norandrostenedione was identified by crystallization to constant specific activity; 19-nortestosterone is a minor product. Production of 19-norandrostenedione and 19-nortestosterone indicates that granulosa cells possess the enzymes necessary for the transformation of 5(10)-estrene-3 beta,17 beta-diol and other 3-hydroxy-5(10)-estrenes to 19-nor-4-ene-3-ketosteroids. The formation of 5(10)-estrene-3 beta,17 beta-diol and 19-norandrostenedione as substantial metabolites of androstenedione suggest a physiological role for these 19-norsteroids in ovarian follicular development.
...
PMID:Formation and metabolism of 5(10)-estrene-3 beta,17 beta-diol, a novel 19-norandrogen produced by porcine granulosa cells from C19 aromatizable androgens. 341 78
Follicles from hamster ovaries removed at 1000 h of proestrus were incubated for 5 h with the medium changed every hour. Proestrous hamsters were also injected at 1400 h with either 4 mg cycloheximide or saline (control), and follicles were dissected from the ovaries at 1500 h and similarly incubated. During the first hour of incubation, the 1000-h follicles produced picogram amounts of all steroids from progesterone (P4) through estradiol (E2). Thereafter E2, androstenedione (delta) and testosterone (T) accumulation in the medium were reduced by about one-half over the next 4 h, whereas 17 alpha-hydroxyprogesterone (17-OHP) increased to become the dominant steroid. The control follicles incubated at 1500 h produced steroids in nanogram amounts and the granulosa cells in vitro now produced C21 steroids, especially P4. In contrast, throughout the 5-h incubation, the follicles of cycloheximide-treated hamsters accumulated considerably reduced amounts of C21 steroids and this was reflected in granulosal production of P4 at one-half to one-tenth of control levels. The profiles for accumulation of C19 and
C18
steroids by the intact follicles of both groups were superimposable over the 5-h period. Thecal production of delta was unaffected by injection of cycloheximide at 1400 h, which suggests that the theca requires the continued presence of high concentrations of cycloheximide to affect steroidogenesis. Incubation of granulosa cells from cycloheximide-exposed follicles with 10 ng of various steroid precursors restored P4, 17-OHP, E2 and estrone (E1) to the same levels as controls, indicating that the steroidogenic enzymes from 3 beta-ol-dehydrogenase through
aromatase
were unaltered and therefore the lack of sterol precursors was the critical step affected by cycloheximide. Incubation of cycloheximide-treated granulosa cells with 25-hydroxycholesterol led to a 3-fold increase in P4 levels which are still only one-half of control values. This points to decreased accessibility of cholesterol to mitochondrial side-chain cleavage as one of the key events blocked by cycloheximide. The experiments show that after exposure to the proestrous surge of gonadotropins, there is normally a rapid recruitment of the granulosal compartment as a source of C21 steroids and this is a protein-dependent process.
...
PMID:Effects of treatment with cycloheximide at proestrus on subsequent in vitro follicular steroidogenesis in the hamster. 642 78
1
2
3
4
5
6
Next >>